Key Molecular Drivers of Chronic Lymphocytic Leukemia.
Chronic lymphocytic leukemia (CLL) is an adult neoplastic disease of B cells characterized by variable clinical outcomes. Although some patients have an aggressive form of the disease and often encounter treatment failure and short survival, others have more stable disease with long-term survival and little or no need for theraphy. In the past decade, significant advances have been made in our understanding of the molecular drivers that affect the natural pathology of CLL. The present review describes what is known about these key molecules in the context of their role in tumor pathogenicity, prognosis, and therapy.
Department of Medical Laboratory, College of Science, Majmaah University, Al-Zuli, Kingdom of Saudi Arabia; Institute of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, United Kingdom. Electronic address: S.alsaqaby@mu.edu.sa.
Suliman A
SA
Alsagaby
Institute of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, United Kingdom.
Paul
P
Brennan
Institute of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, United Kingdom.
Chris
C
Pepper
D015415:Biomarkers; D014408:Biomarkers, Tumor; D004198:Disease Susceptibility; D015973:Gene Expression Regulation, Leukemic; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000175:diagnosis / Q000209:etiology* / Q000378:metabolism* / Q000628:therapy; D011379:Prognosis; D015398:Signal Transduction
D015415:Biomarkers; D014408:Biomarkers, Tumor
CLL; Molecular drivers; Pathogenicity; Prognosis; Therapy